(S)-5-(2-(cyclopentyloxy)-2-(pyridin-4-yl)ethyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (S)-5-(2-(cyclopentyloxy)-2-(pyridin-4-yl)ethyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
• 化学式: C₂₅H₃₁N₃O
• 分子量: 389.541
• InChiKey: WPUJURAHTWADJH-RUZDIDTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.03
• 重原子数：
  29.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  30.29
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  溴代环戊烷 、 2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5 (2H)-yl)-1-(pyridin-4-yl)ethanol 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 1.08h， 以40 mg的产率得到(S)-5-(2-(cyclopentyloxy)-2-(pyridin-4-yl)ethyl)-2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS OF TREATING DIABETES
  [FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DU DIABÈTE

  摘要：

  描述了氢化吡啶并[4,3-b]吲哚和吡啶[3,4-b]吲哚。这些化合物可能与肾上腺素能受体a2A结合并起拮抗作用。这些化合物也可能与肾上腺素能受体α2β结合并起拮抗作用；或者这些化合物不是肾上腺素能受体α2β的拮抗剂，这些化合物与第二药物一起使用，该第二药物降低或预期降低个体的血压。这些化合物可能在疗法中发挥作用，例如，调节血糖水平，增加胰岛素分泌，并治疗疾病或病况，这些疾病或病况对增加胰岛素产生有反应或预期有反应。特别描述了使用这些化合物治疗2型糖尿病。

  公开号：

  WO2014031165A1

文献信息

• [EN] PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS PYRIDO[4,3-B]INDOLE ET PYRIDO[3,4-B]INDOLE ET MÉTHODES D'UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2014031170A1

  公开（公告）日：2014-02-27

  This disclosure is directed to pyrido[4,3-b]indole and pyrido [3, 4-b] indole derivatives and heterocyclic analogs thereof. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶[3,4-b]吲哚衍生物及其杂环类似物。还提供了包含这些化合物的药物组合物，以及使用这些化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20150315188A1

  公开（公告）日：2015-11-05

  Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 1B . in The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  本文描述了氢化吡啶并[4,3-b]吲哚和吡啶[3,4-b]吲哚。这些化合物可以结合和拮抗肾上腺素受体α2B。这些化合物也可以结合和拮抗肾上腺素受体α1B。这些化合物可以用于治疗，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）降低或抑制钠重吸收。这些化合物也可以用于治疗预计对降低血压有反应的疾病或病况。特别地，本文描述了使用这些化合物治疗心血管和肾脏疾病。
• [EN] COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE L'HYPERTENSION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2014031167A1

  公开（公告）日：2014-02-27

  Hydrogenated pyrido[4,3-b]indoles and pyrido [3, 4-b] indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
• [EN] COMPOUNDS AND METHODS OF TREATING DIABETES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DU DIABÈTE
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2014031165A1

  公开（公告）日：2014-02-27

  Hydrogenated pyrido[4,3-b]indoles and pyrido [3, 4-b] indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2β; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  描述了氢化吡啶并[4,3-b]吲哚和吡啶[3,4-b]吲哚。这些化合物可能与肾上腺素能受体a2A结合并起拮抗作用。这些化合物也可能与肾上腺素能受体α2β结合并起拮抗作用；或者这些化合物不是肾上腺素能受体α2β的拮抗剂，这些化合物与第二药物一起使用，该第二药物降低或预期降低个体的血压。这些化合物可能在疗法中发挥作用，例如，调节血糖水平，增加胰岛素分泌，并治疗疾病或病况，这些疾病或病况对增加胰岛素产生有反应或预期有反应。特别描述了使用这些化合物治疗2型糖尿病。